These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26692242)

  • 1. Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies.
    Julius JM; Hammerstrom A; Wei C; Rajesh R; Bodurka DC; Kurian S; Smith JA
    J Oncol Pharm Pract; 2017 Mar; 23(2):121-127. PubMed ID: 26692242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
    Link H; Nietsch J; Kerkmann M; Ortner P;
    Support Care Cancer; 2016 Jan; 24(1):367-376. PubMed ID: 26081593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab.
    Cheng C; Gallagher EM; Yeh JY; Earl MA
    Anticancer Drugs; 2014 Sep; 25(8):964-9. PubMed ID: 24743519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Granulocyte- colony stimulating factor (G-CSF) use in clinical practice in patients receiving chemotherapy for breast cancer: The Opaline Study].
    Jacot W; Antoine EC; Hacini M; Giron C; Rivière A; Moureau-Zabotto L; Cassin D; Yazbek G; Orfeuvre H; Sakek N; Diab R; Bastit L; Mille D; Azria D
    Bull Cancer; 2015 Dec; 102(12):979-92. PubMed ID: 26597475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
    Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
    Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
    Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
    Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
    Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
    Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy.
    Liu F; Du Y; Cai B; Yan M; Yang W; Wang Q
    J Cancer Res Ther; 2017; 13(5):790-795. PubMed ID: 29237905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
    Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
    Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical study on safety and efficacy of JiSaiXin (recombinant human granulocyte colony stimulating factor injection manufactured in China) for Chinese undergoing chemotherapy.
    Wang L; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(1):299-301. PubMed ID: 25640368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Xie J; Cao J; Wang JF; Zhang BH; Zeng XH; Zheng H; Zhang Y; Cai L; Wu YD; Yao Q; Zhao XC; Mao WD; Jiang AM; Chen SS; Yang SE; Wang SS; Wang JH; Pan YY; Ren BY; Chen YJ; Ouyang LZ; Lei KJ; Gao JH; Huang WH; Huang Z; Shou T; He YL; Cheng J; Sun Y; Li WM; Cui SD; Wang X; Rao ZG; Ma H; Liu W; Wu XY; Shen WX; Cao FL; Xiao ZM; Wu B; Tian SY; Meng D; Shen P; Wang BY; Wang Z; Zhang J; Wang L; Hu XC
    Breast Cancer Res Treat; 2018 Apr; 168(2):389-399. PubMed ID: 29230663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The
    Aagaard T; Reekie J; Roen A; Daugaard G; Specht L; Sengeløv H; Mocroft A; Lundgren J; Helleberg M
    Int J Cancer; 2020 Jan; 146(2):321-328. PubMed ID: 30839100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
    van Dooijeweert C; van der Wall E; Baas IO
    Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.